Login / Signup

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.

Odette S ReifsniderAnuraag R KansalPranav K GandhiLael CraginSarah B BrandEgon PfarrKyle FahrbachAnastasia Ustyugova
Published in: BMJ open diabetes research & care (2021)
Empagliflozin was projected to dominate canagliflozin and be highly cost-effective compared with dapagliflozin and SoC using US healthcare costs.
Keyphrases
  • healthcare
  • cardiovascular disease
  • climate change
  • palliative care
  • type diabetes
  • affordable care act
  • cardiovascular risk factors
  • metabolic syndrome
  • health information
  • health insurance
  • chronic pain